Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: TTH006
MIFTS: 53

Tooth Disease

Categories: Oral diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Tooth Disease

About this section

MalaCards integrated aliases for Tooth Disease:

Name: Tooth Disease 12 15
Tooth Diseases 44 73
Tooth Disorders 43

Classifications:

MalaCards categories:
Anatomical: Oral diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:1091
MeSH 44 D014076
UMLS 73 C0040435
Sources

Summaries for Tooth Disease

About this section
MedlinePlus : 43 Your teeth are made of a hard, bonelike material. Inside the tooth are nerves and blood vessels. You need your teeth for many activities you may take for granted. These include eating, speaking and even smiling. But tooth disorders are nothing to smile about. They include problems such as cavities (also known as tooth decay), infections, and injuries. The most familiar symptom of a tooth problem is a toothache. Others include worn-down or loose teeth. It's important that you see a dentist if you have any problems with your teeth. Fortunately, you can prevent many tooth disorders by taking care of your teeth and keeping them clean.

MalaCards based summary : Tooth Disease, also known as tooth diseases, is related to charcot-marie-tooth disease, axonal, type 2j and charcot-marie-tooth disease, x-linked dominant, 1, and has symptoms including halitosis, snoring and toothache. An important gene associated with Tooth Disease is MPZ (Myelin Protein Zero), and among its related pathways/superpathways is Neural Crest Differentiation. The drugs Acetylcholine and Chlorhexidine have been mentioned in the context of this disorder. Affiliated tissues include bone, testes and heart, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Tooth Disease

About this section

Diseases related to Tooth Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 251)
# Related Disease Score Top Affiliating Genes
1 charcot-marie-tooth disease, axonal, type 2j 34.9 KIF1B MPZ
2 charcot-marie-tooth disease, x-linked dominant, 1 34.9 GDAP1 GJB1 MPZ
3 charcot-marie-tooth disease, axonal, type 2a1 34.8 KIF1B MFN2
4 charcot-marie-tooth disease, axonal, type 2i 34.7 KIF1B MPZ
5 charcot-marie-tooth disease, demyelinating, type 4f 34.7 GDAP1 MTMR2 SBF2
6 charcot-marie-tooth disease, type 4b2 34.7 GDAP1 MTMR2 SBF2
7 charcot-marie-tooth disease, type 4b1 34.7 GDAP1 MTMR2 SBF2
8 charcot-marie-tooth disease, type 4a 34.7 GDAP1 MTMR2 SBF2
9 charcot-marie-tooth disease, type 4b3 34.6 GDAP1 MTMR2 SBF2
10 charcot-marie-tooth disease, axonal, type 2q 34.6 EGR2 MPZ
11 charcot-marie-tooth disease, type 4j 34.6 FIG4 MTMR2 SBF2
12 charcot-marie-tooth disease, demyelinating, type 1f 34.5 GJB1 MPZ NEFL PMP22
13 charcot-marie-tooth disease type 2a 34.5 KIF1B MFN2
14 charcot-marie-tooth disease, axonal, type 2f 34.4 GJB1 HSPB1 KIF1B MPZ
15 charcot-marie-tooth disease, axonal, type 2b 34.4 EGR2 GJB1 KIF1B MPZ PMP22
16 charcot-marie-tooth disease, demyelinating, type 1c 34.2 KIF1B LITAF MPZ NEFL PMP22
17 charcot-marie-tooth disease, type 4d 34.1 GDAP1 GJB1 MFN2 NDRG1 SH3TC2
18 charcot-marie-tooth disease, demyelinating, type 1b 34.1 EGR2 GJB1 KIF1B MPZ MTMR2 PMP22
19 charcot-marie-tooth disease, axonal, type 2k 34.1 GDAP1 HSPB8 KIF1B MFN2
20 charcot-marie-tooth disease, axonal, type 2l 33.9 HSPB1 HSPB8 KIF1B MPZ
21 roussy-levy hereditary areflexic dystasia 33.9 MPZ PMP22
22 charcot-marie-tooth disease, x-linked recessive, 3 33.8 GJB1 HSPB8
23 charcot-marie-tooth disease, demyelinating, type 1a 33.6 EGR2 GDAP1 GJB1 KIF1B MFN2 MPZ
24 neuropathy, hereditary motor and sensory, russe type 33.5 EGR2 NDRG1 SH3TC2
25 charcot-marie-tooth disease, demyelinating, type 1d 33.4 EGR2 GJB1 KIF1B MPZ MTMR2 NDRG1
26 hereditary motor and sensory neuropathy, type iic 33.2 GDAP1 GJB1 KIF1B MFN2 MPZ NDRG1
27 charcot-marie-tooth disease and deafness 33.0 EGR2 GDAP1 GJB1 KIF1B LITAF MFN2
28 foot drop 32.9 MPZ PMP22
29 congenital hypomyelination neuropathy 32.6 MPZ PMP22
30 hypertrophic neuropathy of dejerine-sottas 32.5 EGR2 GDAP1 GJB1 KIF1B LITAF MPZ
31 charcot-marie-tooth disease, axonal, type 2e 32.0 EGR2 GDAP1 GJB1 KIF1B LMNA LRSAM1
32 hereditary neuropathy with liability to pressure palsy 31.4 LITAF MPZ PMP22
33 hereditary neuropathies 31.1 GJB1 HSPB1 LMNA MFN2 MPZ MTMR2
34 polyneuropathy 31.1 GDAP1 MPZ PMP22
35 neuropathy 31.1 EGR2 GDAP1 GJB1 MFN2 MPZ PMP22
36 axonal neuropathy 30.6 GDAP1 LMNA MFN2 PMP22
37 cauda equina syndrome 30.4 EGR2 PMP22
38 early-onset glaucoma 30.2 MTMR2 SBF2
39 neuropathy, hereditary, with liability to pressure palsies 30.1 EGR2 GDAP1 GJB1 KIF1B LITAF MFN2
40 peripheral nervous system disease 29.9 EGR2 GDAP1 GJB1 MFN2 MPZ MTMR2
41 neuropathy, congenital hypomyelinating or amyelinating, autosomal recessive 29.6 EGR2 FGD4 FIG4 GDAP1 GJB1 HSPB8
42 sensory peripheral neuropathy 29.2 FGD4 GDAP1 GJB1 LITAF MFN2 MPZ
43 amyotrophic lateral sclerosis 1 28.6 FIG4 HSPB1 HSPB8 NEFL
44 charcot-marie-tooth disease 28.3 EGR2 FGD4 FIG4 GDAP1 GJB1 HSPB1
45 charcot-marie-tooth disease, type 4h 12.4
46 charcot-marie-tooth disease, axonal, type 2d 12.4
47 charcot-marie-tooth disease, type 4c 12.4
48 charcot-marie-tooth disease, axonal, type 2p 12.4
49 charcot-marie-tooth disease, axonal, type 2n 12.3
50 charcot-marie-tooth disease, axonal, type 2b1 12.3

Graphical network of the top 20 diseases related to Tooth Disease:



Diseases related to Tooth Disease
Sources

Symptoms & Phenotypes for Tooth Disease

About this section

UMLS symptoms related to Tooth Disease:


halitosis, snoring, toothache, poor dentition

GenomeRNAi Phenotypes related to Tooth Disease according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.37 GJB1
2 Decreased viability GR00107-A-1 10.37 HSPB8
3 Decreased viability GR00221-A-1 10.37 HSPB8
4 Decreased viability GR00221-A-4 10.37 HSPB8
5 Decreased viability GR00240-S-1 10.37 LMNA
6 Decreased viability GR00301-A 10.37 HSPB8
7 Decreased viability GR00381-A-1 10.37 LRSAM1 MPZ FGD4 FIG4 HSPB1 SH3TC2
8 Decreased viability GR00381-A-3 10.37 MPZ
9 Decreased viability GR00402-S-2 10.37 HSPB8 KIF1B LITAF LMNA LRSAM1 MED25
10 no effect GR00402-S-1 9.62 FIG4 GDAP1 GJB1 HSPB1 HSPB8 KIF1B
11 Increased gamma-H2AX phosphorylation GR00053-A 9.56 EGR2 GJB1 HSPB1 LMNA MPZ NDRG1

MGI Mouse Phenotypes related to Tooth Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.33 MPZ MTMR2 NDRG1 NEFL PMP22 SBF2
2 homeostasis/metabolism MP:0005376 10.13 EGR2 GDAP1 GJB1 HSPB1 HSPB8 KIF1B
3 cellular MP:0005384 10.11 EGR2 GDAP1 GJB1 HSPB1 HSPB8 LITAF
4 mortality/aging MP:0010768 9.97 HSPB8 KIF1B LMNA MED25 MFN2 MPZ
5 limbs/digits/tail MP:0005371 9.86 LMNA MED25 MTMR2 PMP22 EGR2 FIG4
6 muscle MP:0005369 9.56 FIG4 HSPB8 KIF1B LMNA MFN2 NDRG1
7 nervous system MP:0003631 9.55 EGR2 FGD4 FIG4 GDAP1 GJB1 KIF1B
Sources

Drugs & Therapeutics for Tooth Disease

About this section

Drugs for Tooth Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 406)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 4,Phase 1 51-84-3 187
2
Chlorhexidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55-56-1 9552079 2713
3
Tea tree oil Approved Phase 4,Not Applicable
4
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
5
Ephedrine Approved Phase 4 299-42-3 9294
6
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 137-58-6 3676
7
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
8
Phenylephrine Approved Phase 4 59-42-7 6041
9
Pseudoephedrine Approved Phase 4 90-82-4 7028
10
Tetracaine Approved, Vet_approved Phase 4 94-24-6 5411
11
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
12
Hydrocortisone Approved, Vet_approved Phase 4,Early Phase 1,Not Applicable 50-23-7 5754
13
Hydrogen peroxide Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 7722-84-1 784
14 sodium fluoride Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7681-49-4
15
Diclofenac Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 15307-86-5 3033
16
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 26787-78-0 33613
17
Clindamycin Approved, Vet_approved Phase 4,Not Applicable 18323-44-9 29029
18
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 69-72-7 338
19
Ibuprofen Approved Phase 4,Phase 3,Phase 2,Not Applicable 15687-27-1 3672
20
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-61-6, 62-31-7 681
21
Methamphetamine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 537-46-2 10836
22
Miconazole Approved, Investigational, Vet_approved Phase 4,Not Applicable,Early Phase 1 22916-47-8 4189
23
Sorbitol Approved Phase 4,Phase 2,Phase 3,Not Applicable 50-70-4 5780
24
Ethanol Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 64-17-5 702
25
Menthol Approved Phase 4,Phase 2,Not Applicable 2216-51-5 16666
26
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Not Applicable,Early Phase 1 50-02-2 5743
27
Ketamine Approved, Vet_approved Phase 4,Phase 2 6740-88-1 3821
28
Codeine Approved, Illicit Phase 4,Phase 3,Phase 2 76-57-3 5284371
29
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 93-14-1 3516
30
Esomeprazole Approved, Investigational Phase 4,Phase 1,Phase 2 161796-78-7, 119141-88-7 4594 9579578
31
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 22204-53-1 1302 156391
32
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 51-43-4 5816
33
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 329-65-7 838
34
Piroxicam Approved, Investigational Phase 4,Phase 3,Not Applicable 36322-90-4 5280452 54676228
35
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
36
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
37
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 3 59467-70-8 4192
38
Mepivacaine Approved, Vet_approved Phase 4,Not Applicable 96-88-8 4062
39
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 27203-92-5 33741
40
Ketoprofen Approved, Vet_approved Phase 4 22071-15-4 3825
41
Alginic acid Approved, Investigational Phase 4,Not Applicable 9005-32-7
42
Silicon Approved, Investigational Phase 4,Phase 3,Not Applicable 7440-21-3 4082203
43
Cetylpyridinium Approved Phase 4,Phase 3,Phase 2,Phase 1 7773-52-6
44
Triclosan Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 3380-34-5 5564
45
Cimetidine Approved, Investigational Phase 4,Not Applicable 51481-61-9 2756
46
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 103-90-2 1983
47
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2 2180-92-9, 38396-39-3 2474
48
Hydrocodone Approved, Illicit Phase 4,Phase 2,Not Applicable 125-29-1 5284569
49
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 76-42-6 5284603
50
Capsaicin Approved Phase 4 404-86-4 1548943

Interventional clinical trials:

(show top 50) (show all 1364)
# Name Status NCT ID Phase Drugs
1 Success Rate Evaluation of Miniature Pulpotomy With MTA in Primary Molars Unknown status NCT02286648 Phase 4 Formocresol;Mineral Trioxide Aggregate
2 Success and Color Stability of MTA Pulpotomized Primary Molars: an RCT Unknown status NCT02702505 Phase 4
3 Study of the Safety and Efficacy of Botox in Bruxism Unknown status NCT00908050 Phase 4 Botulinum toxin type A
4 Effect of Different Mouthrinses in Plaque Formation Unknown status NCT02695901 Phase 4 Chlorhexidine gluconate 0.12% (PerioGard®);Nanoparticle solution of M. alternifolia oil (0.3%).
5 Consumption Effect of Probiotic Products on Salivary Cariogenic Bacterial Counts in Preschool Children. Unknown status NCT02692625 Phase 4
6 Dental Caries Management by Risk Assessment: Identification and Treatment of Risk Factors Among (IDF) Personnel Unknown status NCT01142440 Phase 4
7 Manually Versus Digitally Fabricated Removable Partial Dentures Unknown status NCT01191073 Phase 4
8 Elmex Gel Efficacy in Preventing White Spot Lesions Unknown status NCT00268138 Phase 4 elmex gel
9 Clinical Comparison of RPDs Retained by Conical and Galvanoformed Double Crowns. Unknown status NCT00176215 Phase 4
10 Evaluation of a Lateral Window Technique Augmentation for Maxillary Sinus Using Ultrasound Activated Pins Unknown status NCT02449707 Phase 4
11 Effects of Botulinum Toxin Type A(Meditoxin®) on Sleep Bruxism Unknown status NCT01336439 Phase 4 Botulinum toxin type A (Meditoxin®)
12 Anticaries Effect of Probiotic Lactobacillus Brevis CD2 (Lb CD2). Unknown status NCT01778699 Phase 4
13 Comparative Efficacy of 20% Benzocaine Versus TAC Alternate Gel Unknown status NCT00846690 Phase 4 benzocaine;TAC alternate gel
14 Ketamine on Acute Pain in Females and Males Completed NCT00232492 Phase 4 Placebo males;Ketamine 0,1 mg/kg males;Ketamine 0,3 mg/kg males;Ketamine 0,5 mg/kg males;Placebo females;Ketamine 0,1 mg/kg females;Ketamine 0,3 mg/kg females;Ketamine 0,5 mg/kg females
15 Topical Hydrocortisone for Pain and Edema Control After Third Molar Surgery Completed NCT03179813 Phase 4
16 The Effect of Whitening Toothpaste on Tooth Color Associated With Bleaching Process Completed NCT03163069 Phase 4
17 Efficacy of a Whitening Dentifrice on Tooth Discoloration Completed NCT02741427 Phase 4
18 Effectiveness of Diclofenac and Its Association to Codeine After Lower Third Molar Extraction. Completed NCT02547896 Phase 4 Codeine + Diclofenac;Diclofenac
19 Comparison of the Clinical Efficacy of Naproxen, Associated or Not With Esomeprazol, in Lower Third Molar Removal Completed NCT02494856 Phase 4 Surgery with Naproxen;Surgery with Naproxen and Esomeprazole
20 Lower Third Molar Removal With 2% and 4% Articaine Completed NCT02457325 Phase 4 Surgery with 2% articaine;Surgery with 4% articaine
21 Influence of Genotype of CYP2C9 on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar Surgery Completed NCT02450487 Phase 4 Piroxicam
22 AUGMENTINâ„¢ in Dental Infections Completed NCT02141217 Phase 4 Amoxicillin/clavulanate;Clindamycin
23 Longevity and Effectiveness of Bleaching in Healthy and Smokers Patients Completed NCT02017873 Phase 4 Peroxide Carbamide 10% - Dental bleaching treatment
24 An Efficacy Study of Stain Control of a 67% Sodium Bicarbonate Containing Toothpaste on Chlorhexidine Tooth Staining Completed NCT01962493 Phase 4 Chlorhexidine digluconate
25 Effect of AcceleDent® Aura on Orthodontic Tooth Movement With Aligners Completed NCT01962012 Phase 4
26 Clinical Effectiveness of In-office Bleaching Activated With a LED/Laser Device Completed NCT01231243 Phase 4
27 Effectiveness of a Chlorine Dioxide Spray on Dental Plaque and Respiratory Pathogens in Institutionalized Elders Completed NCT03533335 Phase 4
28 Effect of the Amount of Fluoride Toothpaste on Fluoride Availability in the Oral Fluids in Children Completed NCT03455621 Phase 4
29 MI Varnish for the Prevention of White Spot Lesions Completed NCT03446690 Phase 4 MI Varnish
30 Casein Phosphopeptide--amorphous Calcium Phosphate on Human Enamel Subjected to in Vivo Acid Attacks Completed NCT03426150 Phase 4 CPP-ACP;Placebos
31 Treatment of Immature Permanent Teeth With Three Different Pulp Capping Materials With Partial Pulpotomy Completed NCT03426046 Phase 4 Pulp Capping Agents
32 The Effect of Silver Diamine Fluoride (SDF) on Bacteria Involved in Root or Cervical Carious Lesions Completed NCT02953886 Phase 4
33 To Investigate the Efficacy of an Occluding Dentifrice in Dentinal Hypersensitivity (DH) Completed NCT02923895 Phase 4
34 Nano-hydroxyapatite With Potassium Nitrate in the Therapy of the Dental Sensitivity Completed NCT02895321 Phase 4
35 Oral Glucocorticoids Effect on Post Endodontic Pain Completed NCT02819648 Phase 4 Prednisolone
36 Fuji Type VII Sealant Versus Resin Based Sealant. A Clinical Trial Completed NCT02795728 Phase 4
37 Study to Investigate the Efficacy of an Occluding Dentifrice in Providing Relief From Dentine Hypersensitivity Completed NCT02773758 Phase 4
38 Short Term Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity Completed NCT02731833 Phase 4
39 Prevention of Dental Caries Lesions With Fluoride Varnish in Erupting First Permanent Molars Completed NCT02592278 Phase 4 Fluoride Varnish;Control Group
40 Comparison of the Effect of Fluoride Remineralizer Gel and Foam Completed NCT02490592 Phase 4
41 Clinical Study of the Whitening Dentifrices on Tooth Color and Sensitivity Completed NCT02483013 Phase 4
42 Midazolam and Ketamine Effect Administered Through the Nose for Sedation of Children for Dental Treatment Completed NCT02447289 Phase 4 Intranasal ketamine;Oral ketamine;Intranasal midazolam;Oral midazolam
43 MI Varnish and MI Paste Plus in a Caries Prevention and Remineralization Study Completed NCT02424097 Phase 4 CPP-ACP 5% sodium fluoride varnish & 900ppm fluoride paste;1,100pm F-toothpaste and 0.5%NaF rinse
44 Preventive and Therapeutic Proximal Sealants Completed NCT02338180 Phase 4
45 The Effect of Desensitizing Agents in In-home or In-office Dental Bleaching Completed NCT02316080 Phase 4
46 Mepivacaine-Tramadol on the Success of Inferior Alveolar Nerve Block in Symptomatic Irreversible Pulpitis Completed NCT02110966 Phase 4 Mepivacaine;Mepivacaine plus Tramadol
47 Dexketoprofen Trometamol in Postoperative Endodontic Pain Completed NCT02086097 Phase 4 Dexketoprofen trometamol;Ibuprofen;PLACEBO
48 Anesthetic Efficacy in Irreversible Pulpitis Completed NCT02054767 Phase 4 Intervention: inferior alveolar nerve block injection
49 Impact of Maternal Xylitol Consumption on Mutans Sterptococci Completed NCT02036151 Phase 4 xylitol;fluoride varnish application
50 Anesthetic Efficacy of Articaine and Lidocaine in Lower Molars With Irreversible Pulpits Completed NCT01912755 Phase 4 4% articaine with 1:100,000 epinephrine;2% lidocaine with 1:100,000 epinephrine

Search NIH Clinical Center for Tooth Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: tooth diseases

Sources

Genetic Tests for Tooth Disease

About this section
Sources

Anatomical Context for Tooth Disease

About this section

MalaCards organs/tissues related to Tooth Disease:

41
Bone, Testes, Heart, Brain, Spinal Cord, Tonsil, Kidney
Sources

Publications for Tooth Disease

About this section

Articles related to Tooth Disease:

(show top 50) (show all 1073)
# Title Authors Year
1
Coexistence of Amyotrophic Lateral Sclerosis in the Proband of an X-Linked Charcot-Marie-Tooth Disease Type 1 Pedigree in China. ( 29629536 )
2018
2
Six months of strength training reduces progression of dorsiflexor muscle weakness in children with Charcot-Marie-Tooth disease [commentary]. ( 29289585 )
2018
3
Clinical and genetic features of Charcot-Marie-Tooth disease 2F and hereditary motor neuropathy 2B in Japan. ( 29381233 )
2018
4
Myelinated axons fail to develop properly in a genetically authentic mouse model of Charcot-Marie-Tooth disease type 2E. ( 29940160 )
2018
5
Pain in Charcot-Marie-Tooth disease: an update. ( 29742248 )
2018
6
HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease. ( 29415205 )
2018
7
Six months of strength training reduces progression of dorsiflexor muscle weakness in children with Charcot-Marie-Tooth disease [synopsis]. ( 29276065 )
2018
8
Evaluation of muscle strength, balance and functionality of individuals with type 2 Charcot-Marie-Tooth Disease. ( 29674285 )
2018
9
MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A. ( 29674596 )
2018
10
Clinical and genetic investigation in Chinese patients with demyelinating Charcot-Marie-Tooth disease. ( 29896895 )
2018
11
DHTKD1 Deficiency Causes Charcot-Marie-Tooth Disease in Mice. ( 29661920 )
2018
12
Charcot-Marie-Tooth disease type 2A with an autosomal-recessive inheritance: the first report of an adult-onset disease. ( 29215088 )
2018
13
Drosophila Charcot-Marie-Tooth Disease Models. ( 29951817 )
2018
14
A novel mutation of LRSAM1 in a Chinese family with Charcot-Marie-Tooth disease. ( 29341362 )
2018
15
Association of miR-149 polymorphism with onset age and severity in Charcot-Marie-Tooth disease type 1A. ( 29729827 )
2018
16
Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability. ( 29243538 )
2018
17
HADHB mutations cause infantile-onset axonal Charcot-Marie-Tooth disease: A report of two cases. ( 29956646 )
2018
18
Small heat shock protein B3 (HSPB3) mutation in an axonal Charcot-Marie-Tooth disease family. ( 29341343 )
2018
19
Improvement of Neuropathy Symptoms With Treatment of Obstructive Sleep Apnea in a Patient With Charcot-Marie-Tooth Disease. ( 29246265 )
2018
20
Myelin protein zero mutations and the unfolded protein response in Charcot Marie Tooth disease type 1B. ( 29687021 )
2018
21
Neurofilament light, biomarkers, and Charcot-Marie-Tooth disease. ( 29321227 )
2018
22
PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models. ( 29202483 )
2018
23
Cochlear Implantation in Charcot-Marie-Tooth Disease: Case Report and Review of the Literature. ( 29780422 )
2018
24
Substitution impact of highly conserved arginine residue at position 75 in GJB1 gene in association with X-linked Charcot-Marie-tooth disease: A computational study. ( 29111421 )
2018
25
A novel homozygous NDRG1 mutation in a Chinese patient with Charcot-Marie-Tooth disease 4D. ( 29724652 )
2018
26
Genetic analysis of Charcot-Marie-Tooth disease in Denmark and the implementation of a next generation sequencing platform. ( 29653220 )
2018
27
Motor unit number index correlates with disability in Charcot-Marie-Tooth disease. ( 29729594 )
2018
28
Clinical and genetic diversities of Charcot-Marie-Tooth disease with MFN2 mutations in a large case study. ( 29906321 )
2018
29
MARS variant associated with both recessive interstitial lung and liver disease and dominant Charcot-Marie-Tooth disease. ( 29655802 )
2018
30
PFN2 and GAMT as common molecular determinants of axonal Charcot-Marie-Tooth disease. ( 29449460 )
2018
31
Operative treatment algorithm for foot deformities in Charcot-Marie-Tooth disease. ( 29417158 )
2018
32
The spectrum of Charcot-Marie-Tooth disease due to myelin protein zero: An electrodiagnostic, nerve ultrasound and histological study. ( 29136549 )
2018
33
Peripheral neuropathies: Antisense therapy for Charcot-Marie-Tooth disease? ( 29269786 )
2018
34
Testing overwork weakness in Charcot-Marie-tooth disease: Is it true or false? ( 29693294 )
2018
35
Modeling the Pathogenesis of Charcot-Marie-Tooth Disease Type 1A Using Patient-Specific iPSCs. ( 29276154 )
2018
36
Anaesthesia and orphan diseases: anaesthetic management of a patient with X-linked Charcot-Marie-Tooth disease type 1. ( 29870477 )
2018
37
SCO2 mutations cause early-onset axonal Charcot-Marie-Tooth disease associated with cellular copper deficiency. ( 29351582 )
2018
38
Targeted exomes reveal simultaneous MFN2 and GDAP1 mutations in a severe Charcot-Marie-Tooth disease type 2 phenotype. ( 28211244 )
2017
39
Analysis of neural crest cells from Charcot-Marie-Tooth disease patients demonstrates disease-relevant molecular signature. ( 28704293 )
2017
40
Clinical and mutational spectrum of Charcot-Marie-Tooth disease type 2Z caused by MORC2 variants in Japan. ( 28771897 )
2017
41
Mitochondrial trifunctional protein deficiency: an adult patient with similar progress to Charcot-Marie-Tooth disease. ( 28132977 )
2017
42
Severe vincristine-induced polyneuropathy in a teenager with anaplastic medulloblastoma and undiagnosed Charcot-Marie-Tooth disease. ( 28438772 )
2017
43
Charcot-Marie-Tooth Disease Type 1A: Influence of Body Mass Index on Nerve Conduction Studies and on the Charcot-Marie-Tooth Examination Score. ( 28914656 )
2017
44
Aerobic anti-gravity exercise in patients with Charcot-Marie-Tooth disease types 1A and X: A pilot study. ( 29299376 )
2017
45
Mutations in BAG3 cause adult-onset Charcot-Marie-Tooth disease. ( 28754666 )
2017
46
Clinical and genetic diversities of Charcot-Marie-Tooth disease with MFN2 mutations in a large case study. ( 28660751 )
2017
47
LRSAM1-mediated ubiquitylation is disrupted in axonal Charcot-Marie-Tooth disease 2P. (